Trial Profile

A pivotal trial of PLX-PAD in Japanese patients with critical limb ischemia

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 04 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emiplacel (Primary)
Indications Chronic limb-threatening ischemia
Focus Registrational; Therapeutic Use
Sponsors Pluri

Most Recent Events

13 Mar 2023 According to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.
12 Aug 2016 New trial record
02 Aug 2016 According to a Pluristem Therapeutics media release, the company reached an agreement with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) on the protocol of this trial via Japan's accelerated regulatory pathway for regenerative medicine.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com